β-Amyloid 22-35

β-Amyloid 22-35 is a synthetic peptide fragment derived from the central region of the amyloid beta (Aβ) protein, an important biomolecule implicated in neurodegenerative processes. Comprising residues 22 through 35 of the full-length Aβ sequence, this peptide exhibits key aggregation and cytotoxic properties that closely model those of the parent protein, making it a valuable tool in the study of amyloidogenesis. Its relatively short length, combined with a propensity to form fibrillar structures, allows researchers to investigate the core mechanisms of amyloid aggregation, neurotoxicity, and related biochemical pathways under controlled experimental conditions. As such, the peptide holds significant relevance for fundamental research in neurobiology, protein misfolding, and the molecular basis of neurodegenerative diseases.

Peptide aggregation studies: β-Amyloid 22-35 is widely utilized as a model system for elucidating the kinetics and structural characteristics of amyloid fibril formation. Its robust self-assembly into β-sheet-rich aggregates enables detailed investigation into the physicochemical factors that drive peptide aggregation, including sequence determinants, environmental conditions, and the influence of chemical modulators. By monitoring the aggregation process using biophysical techniques such as circular dichroism spectroscopy, thioflavin T fluorescence, and atomic force microscopy, researchers gain insights into the nucleation, elongation, and maturation phases of amyloidogenesis.

Neurotoxicity assays: The peptide fragment serves as a practical agent for assessing the cytotoxic effects of amyloid aggregates on neuronal and glial cell cultures. Due to its capacity to induce oxidative stress, membrane disruption, and apoptotic signaling, β-Amyloid 22-35 is instrumental in modeling the cellular responses associated with amyloid-induced neurodegeneration. Experimental systems employing this peptide facilitate quantitative analysis of cell viability, mitochondrial dysfunction, and intracellular calcium dysregulation, supporting the evaluation of neuroprotective strategies and mechanistic studies of peptide-induced toxicity.

Screening of aggregation inhibitors: Researchers employ β-Amyloid 22-35 in high-throughput screening platforms to identify and characterize small molecules, peptides, or antibodies capable of modulating amyloid aggregation. Its predictable aggregation profile and manageable size make it particularly suitable for rapid assessment of candidate inhibitors, allowing for efficient differentiation between compounds that prevent fibril formation, destabilize preformed aggregates, or alter aggregate morphology. These studies contribute to the discovery and optimization of novel anti-aggregation agents with potential applications in neurodegenerative disease research.

Biophysical characterization of amyloid structures: The peptide is frequently used as a reference system for structural and spectroscopic analyses of amyloid assemblies. Its ability to form well-defined fibrils and oligomers enables detailed examination of secondary structure transitions, intermolecular interactions, and the physicochemical properties of aggregated species. Advanced methodologies such as solid-state NMR, Fourier-transform infrared spectroscopy, and electron microscopy are often applied to β-Amyloid 22-35 samples to elucidate the molecular architecture and dynamics of amyloid aggregates, informing broader principles of protein misfolding and assembly.

Study of membrane interactions: β-Amyloid 22-35 provides a robust platform for investigating the interactions between amyloidogenic peptides and biological membranes. Its amphipathic character allows for the exploration of peptide-induced perturbations in lipid bilayers, including membrane thinning, pore formation, and lipid peroxidation. By employing model membrane systems such as liposomes or supported lipid bilayers, researchers can dissect the mechanisms by which the peptide disrupts membrane integrity, thereby advancing understanding of amyloid-mediated cytotoxicity and informing the design of membrane-targeted therapeutic interventions.

1. Low bone turnover and low BMD in Down syndrome: effect of intermittent PTH treatment

2. Urinary Metabolites Associated with Blood Pressure on a Low-or High-Sodium Die

3. Multifunctional peptide-oligonucleotide conjugate promoted sensitive electrochemical biosensing of cardiac troponin I

4. Immune responses to peptides containing homocitrulline or citrulline in the DR4-transgenic mouse model of rheumatoid arthritis

5. Extended exenatide administration enhances lipid metabolism and exacerbates pancreatic injury in mice on a high fat, high carbohydrate diet